Evotec

Showing 15 posts of 16 posts found.

Evotec and Dewpoint Therapeutics enter strategic partnership

November 7, 2023
Research and Development Dewpoint Therapeutics, Evotec, Oncology, R&D, oncology

Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s oncology pipeline programmes of condensate …

Exscientia enter first-ever AI cancer drug into Phase I trials

April 9, 2021
Medical Communications AI, Evotec, Exscientia, cancer treatment, oncology, pharma, pharma news

Exscientia and Evotec have announced that they are entering an AI-designed immuno-oncology drug into Phase I trials for the first …

Evotec building

Evotec and Chinook to partner on new kidney disease treatments

March 1, 2021
Sales and Marketing CKD, Chinook, Evotec, chronic kidney disease, kidney disease

Evotec and Chinook Therapeutics have agreed a deal to discover and develop new therapies for patients with chronic kidney diseases …

evotec_credit_-_gregor_r

EvoTec to command vast Sanofi resources in infectious disease R&D partnership

March 8, 2018
Research and Development, Sales and Marketing Evotec, Sanofi, infectious disease, infective disease, pharma

Sanofi has announced it is to team up with biotech drug discovery specialist EvoTec to leverage a new open innovation …

R&D

Sanofi, Evotec and Apeiron partner on immuno-oncology

August 10, 2015
Research and Development, Sales and Marketing Apeiron, Cancer, Evotec, Sanofi, immuno-oncology, immunotherapy, tumours

Sanofi is partnering with biotech companies Evotec and Apeiron to develop new cancer immuno-oncology therapies.The companies say the potential new …

Evotec image

Evotec and Sanofi enter pre-clinical deal

December 3, 2014
Research and Development, Sales and Marketing DiaPep277, Evotec, Sanofi, oncology, priftin, toulouse

Evotec and Sanofi have entered negotiations for a major multi-component strategic alliance worth around €250 million over the next five …

Evotec image

Trial misconduct halts Evotec/Hyperion drug

September 10, 2014
Research and Development, Sales and Marketing DiaPep277, Evotec, amdromeda, diabetes, hyperion

Development of Evotec and Hyperion Therapeutic’s diabetes drug DiaPep277 has been terminated following ‘serious misconduct’ in one of its trials. …

screen_shot_2014-04-14_at_10

arGEN-X appoints Evotec chief executive

April 14, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Evotec, arGEN-X, lanthaler

Belgium-based clinical stage human therapeutic antibody firm arGEN-X has appointed Dr Werner Lanthaler to its supervisory board.
  Lanthaler is currently …

Pharma losing in ‘valley of death’

February 21, 2013
Research and Development, Sales and Marketing Bath, Evotec, pharma

An academic from Bath University has warned that much of pharma’s most promising research is being lost before it can …

Bayer image

Bayer signs endometriosis pact

October 3, 2012
Research and Development, Sales and Marketing Bayer, Evotec, endometriosis

Bayer HealthCare and Evotec have signed a five-year deal to look for three novel drugs to treat women with endometriosis. …

Janssen image

Janssen buys into regenerative diabetes portfolio

July 11, 2012
Research and Development, Sales and Marketing CureBeta, Evotec, Janssen, diabetes

Janssen has licensed a portfolio of drugs designed to regenerate insulin-producing beta cells. Janssen will receive exclusive access to a …

Roche

Roche and Evotec to develop Alzheimer’s drug

September 6, 2011
Alzheimer's disease, Evotec, Roche

Roche and Evotec are to collaborate on the development and commercialisation of Evotec’s MAO-B inhibitor in patients with Alzheimer’s disease. …

Roche

Roche and Evotec to collaborate on cancer biomarkers

June 24, 2011
Research and Development Evotec, Roche, biomarkers

Roche and Evotec are to collaborate to find biomarkers for Roche oncology drugs under development. Roche has been one of …

Contract research news in brief

February 23, 2011
Research and Development Bioanalytical Systems, Evotec, Iris Pharma, Kancera, Kinaxo Biotechnologies, NSF International, Pharmalytica Services, iNovacia

Acquisitions by Evotec, Kancera and NSF International head our latest CRO news round-up, along with updates from BASi and Iris …

Evotec wins grant to advance H3 receptor antagonist

May 4, 2010
Research and Development CNS, Evotec, MS

Evotec is to receive funding of up to 1.5 million euros from a German government fund to advance its H3 …

Latest content